8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                   ----------


                                    FORM 8-K


                                 CURRENT REPORT
                     Pursuant to Section 13 Or 15(D) of The
                         Securities Exchange Act of 1934




         Date of report (Date of earliest event reported): May 30, 2003



                              ANTARES PHARMA, INC.
                              --------------------
               (Exact Name of Registrant as Specified in Charter)



          Minnesota                      0-20945                 41-1350192
          ---------                      -------                 ----------
 (State or Other Jurisdiction          (Commission            (I.R.S. Employer
      of Incorporation)                File Number)          Identification No.)



              707 Eagleview Boulevard, Suite 414, Exton, PA   19341
              -----------------------------------------------------
             (Address of Principal Executive Offices)      (Zip Code)



       Registrant's telephone number, including area code: (610) 458-6200


                                 Not Applicable
          -------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)



Item 5.   Other Events and Required FD Disclosure.

       On June 5, 2003, Antares Pharma, Inc. (the "Company") announced that, by
letter dated May 30, 2003, the Listing Qualifications arm of The Nasdaq Stock
Market, Inc. notified the Company that it fails to meet certain independent
director and audit committee requirements as set forth in Nasdaq Marketplace
Rules 4350(c) and 4350(d)(2). The Company is in discussions with Nasdaq
regarding receiving a waiver on this compliance issue.

       A copy of the press release issued by the Company on June 5, 2003, is
attached hereto as Exhibit 99.1

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(c)    Exhibits.

       99.1   Press Release dated June 5, 2003.



                                    SIGNATURE

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Date: June 5, 2003

                                      By  /s/ Lawrence M. Christian
                                        ---------------------------------
                                         Lawrence M. Christian
                                         Chief Financial Officer



                                  EXHIBIT INDEX

       99.1   Press Release dated June 5, 2003.

EX-99.1

                                                                    EXHIBIT 99.1

[Logo of Antares
             Pharma]


Contact Information
Dr. Roger Harrison         CEO and President                      (610) 458-6200
Lawrence M. Christian      CFO and Vice President - Finance       (610) 458-6200
Jay M. Green               Managing Director, Duncan Capital      (212) 581-5150

                    ANTARES PHARMA ANNOUNCES NASDAQ NOTICE OF
     LISTING QUALIFICATION DEFICIENCY REGARDING AUDIT COMMITTEE COMPOSITION

Exton, Pennsylvania - June 5, 2003 - Antares Pharma, Inc. (Nasdaq: ANTR) today
announced that it has received a notice from the Nasdaq Listing Qualifications
Staff indicating that the Company fails to comply with the independent directors
and audit committee composition requirements for continued listing set forth in
Marketplace Rules 4350(c) and 4350(d)(2). Specifically, one of Antares Pharma's
directors who is a member of the audit committee does not meet the independence
standard set forth in the Marketplace Rules because, within the previous three
years, he was the Chief Operating Officer of Permatec Holding AG (the company
with which Antares Pharma combined in 2001). Because this member will become
eligible for independent director status in October 2003, Antares Pharma is in
discussions with the Listing Qualifications Staff regarding receiving a waiver
from Nasdaq on this compliance issue.

About Antares Pharma
     Antares Pharma develops pharmaceutical delivery systems, including
needle-free and mini-needle injection systems and transdermal gel technologies.
These delivery systems improve both the efficiency of drug therapies and the
patient's quality of life. The Company's needle-free injection systems for the
delivery of insulin and growth hormone are currently available in more than 20
countries. The Company's transdermal gel products for hormone replacement
therapy have been licensed to partners in the United States, Europe and Asia
Pacific. The most advanced of these are entering Phase III clinical development.
In addition, Antares Pharma has several products under development and is
conducting ongoing research to create new products that combine various elements
of the Company's technology portfolio. Antares Pharma has corporate headquarters
in Exton, Pennsylvania, with research and development facilities in Minneapolis,
Minnesota, and Basel, Switzerland.

     Statements included in this press release that are not historical in nature
are "forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. The Company cautions readers that forward-looking
statements are subject to certain risks and uncertainties, which could cause
actual results to differ materially and which are identified from time to time
in the Company's reports filed with the U.S. Securities and Exchange Commission.
Antares Pharma claims the protection of the Safe Harbor for forward-looking
statements contained in the Private Securities Litigation Reform Act of 1995.

                  For more information, visit Antares Pharma's web site at
     www.antarespharma.com. Information included on the Company's website is not
     incorporated herein by reference or otherwise.